Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RJK002 in ALS
NCT06454682Phase 1Active, not recruiting
- Sponsor
- RJK Biopharma
- Start
- Sep 2023
- Primary completion
- Jun 2025
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of RJK002 in amyotrophic lateral sclerosis (ALS), sponsored by RJK Biopharma. Primary endpoints: Incidence of Adverse Events and Serious Adverse Events at 5 years and Dose Limiting Toxicities at 28 days. Started Sep 2023; status: active, not recruiting.
02
Drugs
RJK002
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT06454682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06454682.